Caribou Biosciences, Inc. (CRBU)

NMS – Real Time Price. Currency in USD

2.03

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

2.09

+0.06 (2.71%)

After-hours: May 12, 2026, 7:50 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Caribou Biosciences, Inc. (CRBU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Three Best Genomics Stocks for Your Portfolio in 2026

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Videos

No Data

Press releases

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Search stocks

Caribou Biosciences, Inc. (CRBU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Three Best Genomics Stocks for Your Portfolio in 2026

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Videos

No Data

Press releases

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy